Clinical Trial Update: A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the efficacy, safety, and immunogenicity of GNR-127 (a recombinant ABP antigen carrying birch pollen BET V 1 and apple MAL…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• GNR-127

Snippet

Sponsor: AO GENERIUM | Conditions: Rhinitis, Allergic, Seasonal | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING